[A 10-day sequential therapy for eradication of Helicobacter pylori infection in children]

Jing Huang1, Si-tang Gong, Wen-ji Ou

  • 1Department of Gastroenterology, Guangzhou Women and Children's Medical Center, Guangzhou, China.

Insights

The 10-day sequential therapy effectively eradicates Helicobacter pylori (Hp) infection in children, showing higher success rates than 7-day and 10-day triple therapies. This regimen offers a promising alternative for pediatric Hp treatment.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Helicobacter pylori (Hp) infection is a common cause of abdominal pain in children.
  • Effective eradication therapies are crucial to prevent long-term complications.
  • Optimizing treatment regimens for pediatric populations is an ongoing clinical challenge.

Purpose of the Study:

  • To evaluate the clinical efficacy of a 10-day sequential therapy for eradicating Hp infection in children.
  • To compare the Hp eradication rates of a 10-day sequential regimen with various triple therapy durations (7, 10, and 14 days).

Main Methods:

  • A randomized controlled trial involving 214 children with confirmed Hp infection.
  • Four treatment groups: 10-day sequential therapy, 7-day triple therapy, 10-day triple therapy, and 14-day triple therapy.
  • Efficacy assessed using the (13)C urea breath test four weeks post-treatment.

Main Results:

  • The 10-day sequential therapy achieved significantly higher Hp eradication rates (85.2% ITT, 90.2% PP) compared to 7-day (66.0% ITT, 71.4% PP) and 10-day triple therapies (60.0% ITT, 67.3% PP).
  • No significant difference in eradication rates was observed between the 10-day sequential therapy and the 14-day triple therapy.
  • All groups showed comparable rates of abdominal pain relief and adverse reactions.

Conclusions:

  • The 10-day sequential regimen is a highly effective treatment for eradicating Hp infection in children.
  • This regimen demonstrates superior efficacy over shorter triple therapy durations.
  • While effective, the 10-day triple regimen offers advantages in treatment duration and patient compliance.
Abstract

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.